

Muhammad K Nisar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4852813/publications.pdf>

Version: 2024-02-01

62
papers

587
citations

1051969

10
h-index

685536

24
g-index

62
all docs

62
docs citations

62
times ranked

1103
citing authors

#	ARTICLE	IF	CITATIONS
1	POS1488-HPRâ€¦CAN A SPECIALIST NURSE LEAD A COMPREHENSIVE OSTEOPOROSIS SERVICE WITH REMOTE SUPERVISION â€“ AN INNOVATIVE CONCEPT. Annals of the Rheumatic Diseases, 2021, 80, 1028.2-1029.	0.5	0
2	POS1478-HPRâ€¦NURSE LED REMOTE MANAGEMENT OF OSTEOPOROSIS â€“ DO PATIENTS APPROVE?. Annals of the Rheumatic Diseases, 2021, 80, 1024.1-1024.	0.5	0
3	Biomarkers Predict In-Hospital Major Adverse Cardiac Events in COVID-19 Patients: A Multicenter International Study. Journal of Clinical Medicine, 2021, 10, 5863.	1.0	9
4	EP15â€¦Switching to biosimilar adalimumab: a real world study. Rheumatology, 2020, 59, .	0.9	0
5	EP43â€¦Biologic retention in psoriatic arthritis: a real world study. Rheumatology, 2020, 59, .	0.9	0
6	P272â€¦How well are conventional DMARDs tolerated in PsA: a real-world study. Rheumatology, 2020, 59, .	0.9	0
7	P89â€¦Can we manage osteoporosis without patients ever seeing a consultant?. Rheumatology, 2020, 59, .	0.9	0
8	EP22â€¦Teriparatide use in the real world: can we expect cost savings with a switch to generic version?. Rheumatology, 2020, 59, .	0.9	0
9	P114â€¦Which antibody is more important for radiographic erosions in RA?. Rheumatology, 2020, 59, .	0.9	0
10	AB1183â€¦TERIPARATIDE SWITCH TO BIOSIMILAR - IS IT COST EFFECTIVE?. Annals of the Rheumatic Diseases, 2020, 79, 1882.1-1882.	0.5	0
11	AB1220â€¦DO ANTIBODIES HAVE DIFFERENTIAL EFFECT ON RADIOGRAPHIC PROGRESSION IN RA?. Annals of the Rheumatic Diseases, 2020, 79, 1901.1-1901.	0.5	0
12	SAT0648-HPRâ€¦CAN A SPECIALIST NURSE REPLACE A CONSULTANT - AN INNOVATIVE MODEL FOR OSTEOPOROSIS CARE. Annals of the Rheumatic Diseases, 2020, 79, 1283.1-1283.	0.5	0
13	The Differential Effect of Antibodies on Radiographic Progression in Rheumatoid Arthritis. Mediterranean Journal of Rheumatology, 2020, 31, 393.	0.3	1
14	Does biologic survival depend on co-prescribed methotrexate dose in established rheumatoid arthritis? A real-world study. European Journal of Rheumatology, 2020, 7, 21-25.	1.3	0
15	204â€¦Switching to biosimilar rituximab: a real world study. Rheumatology, 2019, 58, .	0.9	4
16	121â€¦Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis: a novel approach. Rheumatology, 2019, 58, .	0.9	0
17	122â€¦Secukinumab and solid organ cancer: are they mutually exclusive?. Rheumatology, 2019, 58, .	0.9	0
18	147â€¦Do dedicated early arthritis clinics improve psoriatic arthritis outcomes? A real world study. Rheumatology, 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
19	E028â€fRituximab biosimilar and miliary tuberculosis: vigilance is the key. Rheumatology, 2019, 58, .	0.9	1
20	180â€fDoes the quality & outcomes framework (QOF) indicator for osteoporosis work? A primary care study. Rheumatology, 2019, 58, .	0.9	0
21	Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis â€“ A novel approach. Biologicals, 2019, 60, 93-94.	0.5	5
22	071â€fDoes biologic retention vary with methotrexate co-prescription dose in established RA? A real world study. Rheumatology, 2019, 58, .	0.9	0
23	Early arthritis clinic is cost-effective, improves outcomes and reduces biologic use. Clinical Rheumatology, 2019, 38, 1555-1560.	1.0	14
24	Early arthritis clinic is effective for rheumatoid and psoriatic arthritides. Rheumatology International, 2019, 39, 657-662.	1.5	7
25	Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach. European Journal of Rheumatology, 2019, 6, 57-58.	1.3	8
26	Crystallising the role of adrenocorticotrophic hormone in the management of acute gout: a review. Clinical and Experimental Rheumatology, 2019, 37, 137-145.	0.4	13
27	Rheumatology nurse specialists and corticosteroids prescriptionâ€”Is it safe?. International Journal of Nursing Studies, 2018, 79, 84-85.	2.5	0
28	Cupping (Hijama) Treatment: Benign or Sinister?. Journal of Patient Safety, 2018, 14, e1-e2.	0.7	0
29	317â€fBSR DMARD guidelines and shared prescribing in primary care: is it reliable?. Rheumatology, 2018, 57, .	0.9	1
30	e03â€fACTH reborn: modernising the evidence. Rheumatology, 2018, 57, .	0.9	0
31	e34â€fIs the dose banding of infliximab cost effective? A real world study. Rheumatology, 2018, 57, .	0.9	0
32	267â€fCan community pharmacy services help early identification of psoriatic arthritis? A novel proof of concept study. Rheumatology, 2018, 57, .	0.9	0
33	071â€fDo dedicated early arthritis clinics improve patient outcomes? A real world study. Rheumatology, 2018, 57, .	0.9	0
34	Adherence to biologic therapy â€“ Does it vary with ethnicity?. Biologicals, 2018, 54, 28-32.	0.5	4
35	015â€fGiant cell hepatitis with CTD and ILD: mycophenolate mofetil treating an elusive multi system disease. Rheumatology, 2018, 57, .	0.9	0
36	274â€fRheumatology nurse specialists and corticosteroid prescribing: is it safe?. Rheumatology, 2018, 57, .	0.9	0

#	ARTICLE	IF	CITATIONS
37	292â€fSwitching to biosimilar rituximab: a real world study. Rheumatology, 2018, 57, .	0.9	1
38	014â€fCombining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: a novel approach. Rheumatology, 2018, 57, .	0.9	1
39	Rheumatology nurse specialists and DMARD education â€“ Is it fit for purpose?. International Journal of Nursing Studies, 2017, 69, 98-99.	2.5	3
40	BHPR: AUDIT AND CLINICAL EVALUATION129.â€fTRAINING RHEUMATOLOGY NURSE SPECIALISTS: WHERE ARE WE NOW?. Rheumatology, 2017, 56, .	0.9	0
41	004.â€fHEADACHE: NOT ALWAYS FIBROMYALGIA. Rheumatology, 2017, 56, .	0.9	0
42	137.â€fRHEUMATOLOGY NURSE SPECIALISTS AND DMARD EDUCATION: IS IT FIT FOR PURPOSE?. Rheumatology, 2017, 56, .	0.9	1
43	E19.â€fDISEASE-MODIFYING ANTI-RHEUMATIC DRUG PRESCRIPTION AND JUNIOR DOCTORS: IS IT SAFE?. Rheumatology, 2017, 56, .	0.9	1
44	005.â€fCHIKUNGUNYA AND SPONDYLOARTHROPATHY: IS THERE AN ASSOCIATION?. Rheumatology, 2017, 56, .	0.9	0
45	E57.â€fADHERENCE TO SUBCUTANEOUS BIOLOGIC THERAPIES: DOES IT VARY WITH ETHNICITY?. Rheumatology, 2017, 56, .	0.9	0
46	Chikungunya and bilateral sacroiliitisâ€“is there a link?. European Journal of Rheumatology, 2017, 4, 81-82.	1.3	1
47	Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom. Clinical Rheumatology, 2015, 34, 2141-2145.	1.0	19
48	What do we know about juvenile idiopathic arthritis and vitamin D? A systematic literature review and meta-analysis of current evidence. Clinical Rheumatology, 2013, 32, 729-734.	1.0	26
49	Lemierreâ€™s syndrome: a rare cause of septic polyarthritis. Rheumatology International, 2013, 33, 817-818.	1.5	3
50	Pulmonary Complications of Biological Therapies in Children and Adults with Rheumatic Diseases. Paediatric Respiratory Reviews, 2013, 14, 236-241.	1.2	4
51	Same-day or historical ESR for disease activity score measurement: does it matter?. Clinical Rheumatology, 2013, 32, 261-265.	1.0	1
52	TNF antagonists and shingles: is vaccination advisable?. Annals of the Rheumatic Diseases, 2013, 72, e1-e1.	0.5	3
53	Comment on: Non-infectious pulmonary toxicity of rituximab: a systematic review: reply. Rheumatology, 2012, 51, 2112-2113.	0.9	0
54	The role of tocilizumab monotherapy in the management of rheumatoid arthritis: a review. International Journal of Clinical Rheumatology, 2012, 7, 9-19.	0.3	3

#	ARTICLE	IF	CITATIONS
55	Non-infectious pulmonary toxicity of rituximab: a systematic review. <i>Rheumatology</i> , 2012, 51, 653-662.	0.9	126
56	Interleukin-6 and cytochrome-P450, reason for concern?. <i>Rheumatology International</i> , 2012, 32, 2601-2604.	1.5	56
57	Musculoskeletal examination and junior doctors: cause for concern?. <i>International Journal of Rheumatic Diseases</i> , 2012, 15, e43-4.	0.9	1
58	A challenging case of gout and failure of anti-TNF therapy- Are current treatments adequate?. <i>International Journal of Rheumatic Diseases</i> , 2011, 14, e42-e43.	0.9	1
59	Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. <i>Clinical Rheumatology</i> , 2011, 30, 1471-1474.	1.0	111
60	Non-infectious pulmonary complications of newer biological agents for rheumatic diseases—a systematic literature review. <i>Rheumatology</i> , 2011, 50, 2297-2305.	0.9	117
61	Spontaneous coronary artery dissection in the context of positive anticardiolipin antibodies and clinically undiagnosed systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 1436-1438.	0.8	22
62	Disease remission the goal of therapy in rheumatoid arthritis. <i>Practitioner</i> , 2010, 254, 17-21, 2.	0.3	19